“Long-term Efficacy and Safety of Ritlecitinib in Adults and Adolescents with Alopecia Areata: 3-year Results from the ALLEGRO-LT Phase 3, Open-label Study” (2025) SKIN The Journal of Cutaneous Medicine, 9(4), p. s582. doi:10.25251/gdd40x24.